Exelixis Competitors and Similar CompaniesClear all
Exelixis's competitors and similar companies include Deciphera Pharmaceuticals, Genocea Biosciences, Northwest Biotherapeutics and Glactone Pharma.
 Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. |  Genocea Biosciences Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. |  Northwest Biotherapeutics Northwest Biotherapeutics is a biotechnology company focused on developing and commercializing immunotherapy products to treat cancer. |  Glactone Pharma Glactone Pharma is a biotech company. It develops a pipeline of STAT3 inhibitors for the use in immuno-oncology and for the treatment of drug-resistant cancers. | ||
Founding Date | Founding Date 1994 | Founding Date 2003 | Founding Date 2006 | Founding Date 1998 | Founding Date 2012 |
Type | Type Public | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Alameda, US HQ | Locations Waltham, US HQ Lawrence, US | Locations Cambridge, US HQ | Locations Bethesda, US HQ | Locations Helsingborg, SE HQ |
Employees | Employees 1,14712% decrease | Employees 35037% increase | Employees 593% decrease | Employees 1721% increase | Employees 6 |
Valuation ($) | Valuation ($) 8.2 b | Valuation ($) 2.2 b | Valuation ($) 5.7 k | Valuation ($) 349.5 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $2.2b (FY, 2024) | Revenue (est.) $163.4m (FY, 2023) | Revenue (est.) $1.6m (FY, 2021) | Revenue (est.) $1.4m (FY, 2024) | Revenue (est.) N/A |
Cost of goods | Cost of goods $76.2m (FY, 2024) | Cost of goods $3.7m (FY, 2023) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $2.1b (FY, 2024) | Gross profit $159.6m (FY, 2023) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income $521.3m (FY, 2024) | Net income ($194.9m) (FY, 2023) | Net income ($33.2m) (FY, 2021) | Net income ($83.8m) (FY, 2024) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 714m | Total funding raised $ 209.5m | Total funding raised $ 135.9m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Deciphera Pharmaceuticals
HQ
Waltham, US
Employees
350↑ 37% increase
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
View companyGenocea Biosciences
HQ
Cambridge, US
Employees
59↓ 3% decrease
Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer.
View companyNorthwest Biotherapeutics
HQ
Bethesda, US
Employees
17↑ 21% increase
Northwest Biotherapeutics is a biotechnology company focused on developing and commercializing immunotherapy products to treat cancer.
View companyGlactone Pharma
HQ
Helsingborg, SE
Glactone Pharma is a biotech company. It develops a pipeline of STAT3 inhibitors for the use in immuno-oncology and for the treatment of drug-resistant cancers.
View company